Cargando…

Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma

Detalles Bibliográficos
Autores principales:	Dührsen, Ulrich, Tometten, Mareike, Kroschinsky, Frank, Ganser, Arnold, Ibach, Stefan, Bertram, Stefanie, Hüttmann, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129096/ https://www.ncbi.nlm.nih.gov/pubmed/34001867 http://dx.doi.org/10.1038/s41408-021-00485-5

Ejemplares similares

Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma
por: Zhao, Defeng, et al.
Publicado: (2014)

Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
por: Sun, Xuefei, et al.
Publicado: (2017)

Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study
por: Zhang, Yan, et al.
Publicado: (2021)

Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience
por: Suleman, Adam, et al.
Publicado: (2022)

Methotrexate toxicity treated with continuous venovenous hemofiltration, leucovorin and glucarpidase
por: Connors, Nicholas J., et al.
Publicado: (2014)

Effects of leucovorin (folinic acid) in the methotrexate-treated rat brain
por: OGUSHI, Naofumi, et al.
Publicado: (2018)

Prophylactic Chemotherapy with Methotrexate Leucovorin in High-Risk Hydatidiform Mole
por: Aminimoghaddam, Soheila, et al.
Publicado: (2020)

P1223: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN（ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE)
por: Tang, Y.
Publicado: (2022)

P1145: PRELIMINARY RESULTS OF PENPULIMAB COMBINED WITH RMA(RITUXIMAB, METHOTREXATE, AND CYTARABINE) FOR NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Shen, Haorui, et al.
Publicado: (2023)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
por: Zhang, Peng‐Fei, et al.
Publicado: (2020)

Cytarabine/dasatinib/rituximab: Reactivation of COVID-19 pneumonia : case report
Publicado: (2020)

Methotrexate and Cytarabine—Loaded Nanocarriers for Multidrug Cancer Therapy. Spectroscopic Study
por: Pentak, Danuta, et al.
Publicado: (2016)

Lomustine, methotrexate and cytarabine chemotherapy as a rescue treatment for feline lymphoma
por: Smallwood, Katherine, et al.
Publicado: (2020)

Salvage chemotherapy with R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) for the treatment of relapsed primary CNS lymphoma
por: Cho, Min-Seok, et al.
Publicado: (2016)

CD 5+ Peripheral B Cell Lymphoma With Transformation to CD 5+ Diffuse Large B Cell Lymphoma in the CNS: A Case Report Treated With Rituximab, High Dose Methotrexate, Cytarabine, and Intrathecal Methotrexate
por: Uczkowski, Dariusz, et al.
Publicado: (2022)

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
por: Leonard, John P., et al.
Publicado: (2019)

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
por: Sehn, L. H., et al.
Publicado: (2022)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
por: Palmieri, R., et al.
Publicado: (2019)

Comparative effect of 6S, 6R and 6RS leucovorin on methotrexate rescue and on modulation of 5-fluorouracil.
por: Zittoun, J., et al.
Publicado: (1991)

A Comparison of Vitamin A and Leucovorin for the Prevention of Methotrexate-Induced Micronuclei Production in Rat Bone Marrow
por: Madhyastha, Sampath, et al.
Publicado: (2008)

Comparison of two doses of leucovorin in severe low-dose methotrexate toxicity – a randomized controlled trial
por: Bhargava, Mudit, et al.
Publicado: (2023)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
por: Bega, Giulia, et al.
Publicado: (2021)

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities()
por: Dennis, M., et al.
Publicado: (2013)

SIRPα(+) macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab
por: Marques-Piubelli, Mario L., et al.
Publicado: (2022)

Rituximab/methotrexate: Lack of efficacy: case report
Publicado: (2022)

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
por: Egle, Alexander, et al.
Publicado: (2018)

Reversal of Methotrexate Cytotoxicity to Human Bone Marrow Cells and Leukemic K562 Cells by Leucovorin: Methotrexate Polyglutamates Formation as a Possible Important Factor
por: Koizumi, Shoichi, et al.
Publicado: (1990)

A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome
por: Saygin, Caner, et al.
Publicado: (2020)

5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer
por: Sobrero, A, et al.
Publicado: (2001)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

Rituximab/bendamustine/cytarabine for transplant‐eligible patients with mantle cell lymphoma: A retrospective study
por: Shimizu, Yuki, et al.
Publicado: (2023)

Nucleoside transporter-guided cytarabine-conjugated liposomes for intracellular methotrexate delivery and cooperative choriocarcinoma therapy
por: Fei, Weidong, et al.
Publicado: (2021)

Novel Nanotherapeutic Systems Based on PEGylated Squalene Micelles for Enhanced In Vitro Activity of Methotrexate and Cytarabine
por: Craciun, Bogdan-Florin, et al.
Publicado: (2023)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Petrioli, R, et al.
Publicado: (2004)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Alliot, C
Publicado: (2004)

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Nastoupil, L., et al.
Publicado: (2022)

Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia
por: Oosterom, Natanja, et al.
Publicado: (2019)

Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
por: Tisi, Maria Chiara, et al.
Publicado: (2023)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date
por: Yilmaz, Umut, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7moqqea5lufpmvv0ubsc4s1o46